Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. - Wikidata - wikimedia - TriplyDB

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q33938112

about

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Tenofovir induced Fanconi syndrome: a possible pharmacokinetic interaction.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Renal function with use of a tenofovir-containing initial antiretroviral regimen Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study.Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.Population pharmacokinetics of tenofovir in AIDS patients.Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.

P2860

Q28481276-35E124B6-4A6C-476B-A758-B62370D8EEE0 Q28535587-F59D334F-7B12-42DC-AC01-FE0059E5E188 Q31028855-7BC1E908-8CD2-4513-9068-4B26E75E1841 Q33622825-353FC801-AB09-4860-84D4-39FA5DF58BD6 Q34126724-8E749044-E37A-4A2A-B921-5386E5F0C6AE Q34573789-8DA4C7E5-4FE2-4330-8607-DD75AD62221B Q34658079-697292E6-212A-4C55-A6A1-55CC948DC753 Q35363649-67D829E8-A8AF-4CE2-8EAF-95DECE4A4BA1 Q35607723-53F8B8E2-ADAE-498E-A72F-EBC9BD2A29B1 Q35823231-0DF30581-83D6-445A-B814-179D3AD8DBE2 Q36075954-7387A481-F455-4510-B855-D0F7C1B1560C Q36188725-DD621F4A-2C42-4BA6-BDE2-34CA26683983 Q36243626-D30073C1-1FA5-4591-838A-3C13CB67C144 Q36430073-96C0C18B-1433-4583-A064-32BA562B2AF4 Q36650454-DFC38797-4E27-48CF-9AF1-CC2BD4C615D9 Q36727960-B186E918-17D9-47B5-B6FC-FDBCBC1B3BB8 Q36757558-C9577E89-1664-48D4-B6EF-B571A9E8C334 Q36845126-C6C9129A-DFF4-40F3-BB66-F44F5B9FD26D Q36865491-BBD0115F-49CF-4EAD-A7C3-18B0B2979077 Q36905884-9028ED83-73FB-46BA-AF36-0F16F297F87F Q37203867-635F65EB-1F8A-4B94-BC57-F4E9F5FAE163 Q37210864-35237DDF-DCEC-425E-83EE-2B2EED81A5AB Q37215065-23CD4AEB-8FAF-4CF2-B470-972D689C41CD Q37224902-503B5D44-A2A8-4F12-BE4D-123BF3224CFF Q37245017-3F3D5E69-657E-4860-8E04-00CB36D70BEF Q37660709-038EC534-294D-4512-8621-A260E2364ABF Q37713060-74926B59-FA9D-4E63-AD8C-38CC5E27AEE9 Q38798813-CDE2CAA5-70FC-414A-A215-98E5E96A62E3 Q39107383-3A8B8FE8-3CC7-4408-A877-504C02436072 Q39673548-BDFCB585-399E-47CD-9E8C-1823FB0CDE9C Q40100382-CC87C366-3280-4EC2-8A62-E85FCC25460F Q41204065-E3E0EEE6-BADA-4068-AE48-FD0B744911F5 Q42279687-58C8B85D-85EE-467F-9FFE-5F6DF49383AF Q43013478-A3938FFB-0C99-4D3F-A781-02F03F41824F Q45349377-ADCBA063-2462-4C1C-B5D2-CDC4C8924CC9 Q46261840-D5A429D8-75D5-4E74-9436-162BEEED3E36 Q46432681-D5E242C7-76A3-4382-B6A7-9908486CF543 Q46697094-9A6237B4-7BD1-4241-A57D-C6D38BBB8195 Q47628152-8407FCFA-3B85-440C-B93D-58A7F6196A9C Q47633560-6309EA3B-C0A0-46F1-8408-34FC5DF38737

P2860

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q33938112

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Population pharmacokinetics of ...... active antiretroviral therapy.

@ast

Population pharmacokinetics of ...... active antiretroviral therapy.

@en

type

label

Population pharmacokinetics of ...... active antiretroviral therapy.

@ast

Population pharmacokinetics of ...... active antiretroviral therapy.

@en

prefLabel

Population pharmacokinetics of ...... active antiretroviral therapy.

@ast

Population pharmacokinetics of ...... active antiretroviral therapy.

@en

P1433

Q33938112-3EBEE602-4173-4B61-A260-C8A5219C9A01

P1476

Q33938112-8A19C0EF-C028-44B6-86C9-9A70DD5547C8

P2093

Q33938112-2D70627F-E051-449C-9CAF-24DAC080F6FC

Q33938112-377BC79D-C06B-4BAC-825E-66E160010292

Q33938112-4A545494-F599-4EBB-9A1A-F7FA660C6B1A

Q33938112-569424D6-6BF7-4B98-AACF-11521967F8A4

Q33938112-70D769F4-1BF9-4A67-8D45-14048A7DE771

Q33938112-8247BB3F-B71F-40AC-ADBE-CC0430AE0D58

Q33938112-8F2E73A7-F63E-49D7-BF21-610687E44D11

Q33938112-8FAC646E-6CA8-4BE6-9E7B-95960BCFCD1A

Q33938112-A8B6CE4C-04E0-4910-9F3A-53EC459E001A

Q33938112-BFF13E23-D588-4BF7-B692-6E1CFC6AFC23

P2860

Q33938112-1FA65247-A2A3-40FB-A0CB-334C62952CB5

Q33938112-32B9E795-6B2D-46B1-9CDF-58282398C010

Q33938112-3F499829-D060-43EB-81AC-FDA00C874C1D

Q33938112-57512FD5-8786-4FFF-A794-7530B4428CB8

Q33938112-57801970-0E8C-4816-AFBE-65043C5FC5B2

Q33938112-79633D9D-1DC8-44A2-87CE-3294E9AE18E7

Q33938112-8369734D-2B4C-4AAD-9CDA-9467CED469FD

Q33938112-94CE9F25-9EEF-41D6-A625-7B028FA06587

Q33938112-A10274BA-081D-4D32-A118-262343C1967A

Q33938112-C7FFABA7-E5CD-4293-B0AC-58225EA01604

P304

Q33938112-1DA4292C-7128-477F-9822-BA93668F54F3

P31

Q33938112-1E95C6B1-533E-4A4D-B748-EBDC7275D328

P356

Q33938112-B17BF0DE-252B-47D1-A11A-076330B45785

P407

Q33938112-724B7908-FFAC-4BB7-B6E0-4DC19CEA4849

P433

Q33938112-3A7B8F3D-DE0F-4A6F-A186-86F8C3B0E9E9

P478

Q33938112-2AEE1985-69B0-489F-9A83-74711142E651

P50

Q33938112-8A3B82DF-2031-4F29-A6F5-9ED71C6988BF

Q33938112-9C738D53-D023-4C83-B8E9-17E2CF2DCEDA

P577

Q33938112-8A76ED08-7169-44F9-B8F4-A840484C2E5E

P5875

Q33938112-463561A6-BCC0-4444-ACA0-237AD78A26DD

P698

Q33938112-E094BC88-32D2-48C7-8361-D37253A00428

P921

Q33938112-BE07C5F5-A943-4F2A-BAD6-2EE93037BDFB

P932

Q33938112-0741AF42-F12B-40E2-A638-722A5A76F874

P356

AAC.49.8.3361-3366.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetics of ...... active antiretroviral therapy.

@en

P2093

Agnès Lillo-Le Louet

http://www.w3.org/2001/XMLSchema#string

Anne Krivine

http://www.w3.org/2001/XMLSchema#string

Anne Lescoat

http://www.w3.org/2001/XMLSchema#string

Dominique Salmon

http://www.w3.org/2001/XMLSchema#string

Elisabeth Rey

http://www.w3.org/2001/XMLSchema#string

Gérard Pons

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Tréluyer

http://www.w3.org/2001/XMLSchema#string

Laurence Moachon

http://www.w3.org/2001/XMLSchema#string

Nicolas Dupin

http://www.w3.org/2001/XMLSchema#string

Patrick Jaffray

http://www.w3.org/2001/XMLSchema#string

P2860

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

Prediction of creatinine clearance from serum creatinine

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.

Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal.

Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection.

Renal safety of tenofovir in HIV treatment-experienced patients.

P304

3361-3366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.8.3361-3366.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Marc Tréluyer

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7696653

http://www.w3.org/2001/XMLSchema#string

P698

16048948

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

1196246

http://www.w3.org/2001/XMLSchema#string